Assuntos
Leucemia Linfocítica Crônica de Células B/diagnóstico , Úlceras Orais/diagnóstico , Síndromes Paraneoplásicas/diagnóstico , Pênfigo/diagnóstico , Dermatopatias/diagnóstico , Antineoplásicos/uso terapêutico , Biópsia , Diagnóstico Diferencial , Imunofluorescência , Humanos , Leucemia Linfocítica Crônica de Células B/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Síndromes Paraneoplásicas/tratamento farmacológico , Pênfigo/tratamento farmacológico , Esteroides/uso terapêuticoRESUMO
Burkitt lymphoma (BL) is an aggressive form of non-Hodgkin B-cell lymphoma with 3 variants: endemic, sporadic, and immunodeficiency-associated types. The sporadic form, most commonly involving the abdomen and ileocecal region, presents as an abdominal mass, rarely presenting in the orofacial region. A 36-year-old Indian female presented to the Hospital of the University of Pennsylvania for evaluation of a persistent intraoral swelling ulceration of the lower right mandibular alveolar ridge with minimal bony invasion. Progressive systemic symptoms of fatigue, weakness, and fever developed without resolution following treatment for a presumed odontogenic infection in the 4 weeks before presentation. An incisional biopsy revealed a diffuse proliferation of intermediate- to large-sized lymphocytes with multiple small peripheral nucleoli, scant cytoplasm, and nuclear pleomorphism. Nearly all cells displayed Ki67 expression. A final diagnosis of BL was rendered following confirmation of a cMYC translocation by fluorescence in situ hybridization. This article presents a case of the sporadic form of BL with atypical presentation clinically and morphologically, primarily involving the oral soft tissue.
Assuntos
Linfoma de Burkitt/patologia , Neoplasias Gengivais/patologia , Neoplasias Mandibulares/patologia , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Linfoma de Burkitt/tratamento farmacológico , Linfoma de Burkitt/genética , Ciclofosfamida/administração & dosagem , Dexametasona/administração & dosagem , Diagnóstico Diferencial , Doxorrubicina/administração & dosagem , Feminino , Neoplasias Gengivais/tratamento farmacológico , Neoplasias Gengivais/genética , Fator Estimulador de Colônias de Granulócitos/uso terapêutico , Humanos , Infusões Intralesionais , Neoplasias Mandibulares/tratamento farmacológico , Neoplasias Mandibulares/genética , Proteínas Proto-Oncogênicas c-myc/genética , Translocação Genética , Vincristina/administração & dosagemRESUMO
Alzheimer disease (AD) is a progressive neurologic disorder that manifests as memory loss, personality changes, global cognitive dysfunction, and functional impairment. As the United States population continues to age, the prevalence of AD will rise. Accordingly, oral health care providers will be more likely to treat patients affected by this disease; therefore, it is necessary to understand the pharmacologic agents used for the management of AD. This article provides an update of the available drug therapies for AD and discusses their implications on the oral and dental health of patients.